Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc (NQ: APVO )

0.3070 -0.0030 (-0.97%)
Streaming Delayed Price Updated: 12:58 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptevo Therapeutics Inc

< Previous 1 2 3 4 5 6 7 Next >
Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting
SEATTLE, WA / ACCESSWIRE / November 15, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Looking Into Aptevo Therapeutics's Return On Capital Employed
According to data from Benzinga Pro, during Q3, Aptevo Therapeutics's (NASDAQ:APVO) reported sales totaled $3.10 million. Despite a 16.99% increase in earnings, the company posted... 
Via Benzinga
Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights
SEATTLE, WA / ACCESSWIRE / November 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021
Data support Advancement into the Clinic LUND, SWEDEN, and SEATTLE, WA / ACCESSWIRE / November 11, 2021 / Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") today announce... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
Preclinical data demonstrates inhibited tumor cell growth in vitro when paired with a T-cell engager bispecific SEATTLE, WA / ACCESSWIRE / November 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
SEATTLE, WA / ACCESSWIRE / October 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436
SEATTLE, WA / ACCESSWIRE / October 26, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
Lead Clinical Candidate, APVO436, Recently Showed Clinical Activity and Acceptable Safety Profile in Adults with Myelodysplastic Syndrome (MDS) Article outlines a new strategy to employ APVO436 for... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Regencell Bioscience (NASDAQ:RGC)... 
Via Benzinga
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Phase 1 study showed some patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieved a remission with APVO436 after failing 1-8 lines of prior therapies - Data was... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
SEATTLE, WA / ACCESSWIRE / August 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
SEATTLE, WA / ACCESSWIRE / July 16, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
SEATTLE, WA / ACCESSWIRE / June 29, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19 Lead
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Anavex Life Sciences (NASDAQ:AVXL) stock increased by 17.07% to $25.92 during Tuesday's regular session. As of 12:33 EST, this security is trading at a volume... 
Via Benzinga
48 Biggest Movers From Yesterday
Gainers Lydall, Inc. (NYSE: LDL) shares jumped 85.4% to close at $61.72 on Monday after the company agreed to be acquired by Unifrax for $61.10 per share. New Concept Energy,... 
Via Benzinga
Mid-Afternoon Market Update: Dow Jumps Over 500 Points; Lydall Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 1.71% to 33,857.87 while the NASDAQ rose 0.63% to 14,119.16. The S&P also rose, gaining 1.28% to 4,219.92. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Anavex Life Sciences (NASDAQ:AVXL) shares moved upwards by 17.07% to $25.92 during Monday's regular session. Anavex Life Sciences's stock is trading at a... 
Via Benzinga
31 Stocks Moving In Monday's Mid-Day Session
Gainers Lydall, Inc. (NYSE: LDL) shares climbed 82.3% to $60.68 after the company agreed to be acquired by Unifrax for $61.10 per share. Raven Industries, Inc. (NASDAQ: RAVN)... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; CNH Industrial To Buy Raven Industries
Following the market opening Monday, the Dow traded up 1.27% to 33,712.27 while the NASDAQ rose 0.32% to 14,075.68. The S&P also rose, gaining 0.87% to 4,202.85. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Aptevo Therapeutics Insights: Return On Capital Employed
In Q1, Aptevo Therapeutics (NASDAQ:APVO) posted sales of $2.42 million. Earnings were up 1.01%, but Aptevo Therapeutics still reported an overall loss of $6.89 million. In Q4,... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Clearside Biomedical (NASDAQ:CLSD) stock moved upwards by 26.21% to $3.81 during Tuesday's regular session. As of 12:30 EST, this security is trading at a... 
Via Benzinga
Looking Into Aptevo Therapeutics's Return On Capital Employed
During Q1, Aptevo Therapeutics's (NASDAQ:APVO) reported sales totaled $2.42 million. Despite a 1.01% in earnings, the company posted a loss of $6.89 million. In Q4, Aptevo... 
Via Benzinga
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
Initiates Multi-Center, Multi-Arm Trial Using Active Dose Identified in the Dose Escalation Phase of the Trial SEATTLE, WA / ACCESSWIRE / May 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo")... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Aptevo Stock Gains on Encouraging Single-Agent Activity for APVO436 In Leukemia Patients
Aptevo Therapeutics Inc (NASDAQ: APVO) has announced positive results from Phase 1 dose-escalation trial evaluating lead ADAPTIR candidate, APVO436, for acute... 
Via Benzinga
Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
- Dose Escalation Study of APVO436 Shows Favorable Safety Profile and No Severe Neutropenia, a Potentially Life-threatening Side Effect, Reported in a Significant Number of Patients Receiving... 
From Aptevo Therapeutics
Via AccessWire
Topics Death Intellectual Property
Exposures COVID-19 Death Intellectual Property
Aptevo Therapeutics Reports First Quarter 2021 Financial Results
Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing SEATTLE, WA / ACCESSWIRE / May 11, 2021 / Aptevo... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
SEATTLE, WA / ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.